Therapy News and Research

RSS

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies.

11 Nov 2014

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost. Doctoral researcher Diederik De Cock (KU Leuven) describes the strategy in a new study published in Annals of Rheumatic Diseases.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

FDA approves ImThera Medical's investigational device exemption for pivotal study

ImThera Medical, Inc., a privately held global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its THN3 Clinical Study.

10 Nov 2014

New vaccination approach can reduce tumor burden, suppress formation of lung metastases

In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

9 Nov 2014

Scientists may have discovered new way to repair damaged tissue

By transforming human scar cells into blood vessel cells, scientists at Houston Methodist may have discovered a new way to repair damaged tissue. The method, described in an upcoming issue of Circulation (early online), appeared to improve blood flow, oxygenation, and nutrition to areas in need.

9 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).

7 Nov 2014

Induced neural stem cells hold promise for therapeutic transplantation

Induced neural stem cells (iNSCs) created from adult cells hold promise for therapeutic transplantation, but their potential in this capacity has been limited by failed efforts to maintain such cells in the desirable multi-potent NSC state without continuous expression of the transcription factors used initially to reprogram them.

7 Nov 2014

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin (trade name: Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed despite prior drug therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups.

7 Nov 2014

Liposomes can help prevent bacterial toxins from killing human cells

Published in Nature Biotechnology, the study at the University of Liverpool showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells.

7 Nov 2014

Regenerative medicine may offer new standard of advanced treatment for foot and leg ulcers

These are exciting times for regenerative medicine. Unlike conventional medicines, the regenerative approach can potentially work to restore the lost functionality of tissues or organs—the major reason for intensive focus on research and development in the field.

7 Nov 2014

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer.

7 Nov 2014

McLean Hospital lab explores use of stem cell therapy to treat epilepsy

McLean Hospital and Harvard Stem Cell Institute scientists have new evidence that stem cell transplantation could be a worthwhile strategy to help epileptics who do not respond to anti-seizure drugs.

7 Nov 2014

Researchers edging closer to first ever stem cell transplants for people with Parkinson's disease

A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.

7 Nov 2014

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

7 Nov 2014

Scientists develop human stem cell disease model of Parkinson's disease in a dish

A team of scientists led by The New York Stem Cell Foundation Research Institute successfully created a human stem cell disease model of Parkinson's disease in a dish. Studying a pair of identical (monozygotic) twins, one affected and one unaffected with Parkinson's disease, another unrelated Parkinson's patient, and four healthy control subjects, the scientists were able to observe key features of the disease in the laboratory, specifically differences in the patients' neurons' ability to produce dopamine, the molecule that is deficient in Parkinson's disease.

6 Nov 2014

New AGA guidelines provide guidance on IBS treatments

Up to 15 percent of the general adult population is affected by irritable bowel syndrome (IBS), and most patients struggle to find effective drug therapy. A new guideline from the American Gastroenterological Association provides these patients and their physician's guidance.

6 Nov 2014

Therapy News and Research

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Endothelin gene expression linked to vision loss in premature babies

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

FDA approves ImThera Medical's investigational device exemption for pivotal study

New vaccination approach can reduce tumor burden, suppress formation of lung metastases

Scientists may have discovered new way to repair damaged tissue

Johnson & Johnson completes acquisition of Alios BioPharma

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Induced neural stem cells hold promise for therapeutic transplantation

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Liposomes can help prevent bacterial toxins from killing human cells

Regenerative medicine may offer new standard of advanced treatment for foot and leg ulcers

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

McLean Hospital lab explores use of stem cell therapy to treat epilepsy

Researchers edging closer to first ever stem cell transplants for people with Parkinson's disease

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Scientists develop human stem cell disease model of Parkinson's disease in a dish

New AGA guidelines provide guidance on IBS treatments

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News